Mankind Pharma Limited will participate in three investor conferences in Mumbai on August 13 and 17, 2026, providing analysts and investors with direct access to company management. The engagements, comprising one-on-one and group meetings, are designed to discuss the general business outlook using only information already available in the public domain. This proactive engagement allows stakeholders to gauge management sentiment ahead of upcoming reporting periods.

The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Hitesh Kumar Jain, Company Secretary & Compliance Officer, signed the intimation on August 10, 2026. The notice was submitted to both BSE Limited and National Stock Exchange of India Limited.

The schedule for the upcoming conferences is as follows:

The company emphasized that no unpublished price sensitive information (UPSI) will be disclosed during these interactions. All discussions will remain within the bounds of publicly available data. This standard compliance measure ensures equal access to information for all market participants while preventing insider trading risks.

The intimation has also been uploaded to the company’s website at www.mankindpharma.com for broader accessibility. While the schedule is subject to change due to exigencies on either side, the confirmed dates provide a clear window for institutional and retail investors to seek clarifications on strategic initiatives.

What the Numbers Show

The decision to participate in multiple high-profile conferences, including the Motilal Oswal 22nd Annual Global Investor Conference, signals management’s intent to maintain active dialogue with the investment community. By scheduling these meetings in quick succession over a four-day period, Mankind Pharma aims to efficiently address investor queries regarding its operational trajectory and market positioning without delaying routine business activities.

Mankind Pharma shareholders have approved the reappointment of key leadership figures, including Vice Chairman and Managing Director Rajeev Juneja and Whole-time Director Satish Kumar Sharma, while also adopting the audited financial statements for FY26. The resolutions were passed at the company’s Thirty-Fifth Annual General Meeting (AGM) held via video conferencing on August 4, 2026, with all four ordinary resolutions receiving the requisite majority vote.

The meeting commenced at 3:30 p.m. IST and concluded at 4:56 p.m. IST. Executive Chairman Ramesh Juneja presided over the proceedings in the absence of Rajeev Juneja, who was unable to attend due to bereavement in his family. Voting was facilitated through Central Depository Services (India) Limited (CDSL), with remote e-voting available from August 1 to August 3, 2026, and additional e-voting during the AGM itself. A total of 166,703 shareholders were on record as of July 29, 2026, with 143 members participating directly through video conferencing.

Key Resolutions Passed

Shareholders voted on four ordinary resolutions. The promoter group, holding 299,960,612 shares, voted unanimously in favor of all items. Public institutional investors showed strong support for the financial statements and cost auditor ratification but registered dissenting votes for the director reappointments.

The total number of shares voted across all resolutions was approximately 395.9 million, representing a 95.87% turnout of the outstanding share capital. Notably, the ratification of cost auditor fees received near-unanimous support, with only 204 votes cast against the resolution.

Management Updates and Audit Reports

During the meeting, Sheetal Arora, CEO & Whole-time Director, provided updates on business operations, while Ashutosh Dhawan, Global Chief Financial Officer, presented an overview of the financials for FY26. The Chairman informed members that the Statutory Auditors' Report and Secretarial Auditor's Report contained no qualifications or observations.

Joint Statutory Auditors from S.R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Company were present, along with Secretarial Auditor M/s. Amit Gupta & Associates and Cost Auditor M/s. M. K. Kulshreshta & Associates. Mohit Chaurasia & Associates served as the Scrutinizer for the e-voting process, issuing its consolidated report on August 6, 2026.

What the Numbers Show

The high level of shareholder participation, with nearly 96% of shares polled, indicates robust engagement among Mankind Pharma’s investor base. While the promoter group maintained full alignment with management proposals, the dissenting votes from public institutions regarding the reappointment of Rajeev Juneja and Satish Kumar Sharma suggest some divergence in opinion among larger non-promoter stakeholders. However, the overwhelming majority support ensures continuity in the company’s leadership structure. The clean audit reports further reinforce confidence in the company’s governance and financial reporting for FY26.